
Legal and financial questions of Pfizer-Novo-Metsera
Shareholder Primacy
00:00
How Novo Returned with a Higher Upfront Cash Bid
Mike recounts Novo reoffering a more front‑loaded bid, adding indemnities to address litigation and regulatory risks.
Play episode from 16:58
Transcript


